Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

11 Citationer (Scopus)

Abstrakt

Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.
OriginalsprogEngelsk
TidsskriftDrug Design, Development and Therapy
Vol/bind4
Sider (fra-til)107-16
Antal sider10
ISSN1177-8881
StatusUdgivet - 1 jan. 2010

Fingeraftryk

Dyk ned i forskningsemnerne om 'Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders'. Sammen danner de et unikt fingeraftryk.

Citationsformater